Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Glenmark Pharmaceuticals Limited ( (IN:GLENMARK) ) is now available.
Glenmark Pharmaceuticals Limited has received a warning letter from the U.S. FDA concerning its facility in Indore, Madhya Pradesh, following an inspection conducted in February 2025. The company has stated that this warning will not disrupt supplies or affect current revenues from the facility’s operations. Glenmark is committed to addressing the FDA’s concerns promptly and maintaining compliance with CGMP quality standards, emphasizing that no data integrity issues were observed.
More about Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development, manufacture, and marketing of branded and generic formulations. The company is known for its emphasis on innovation and has a significant presence in various therapeutic areas.
Average Trading Volume: 51,290
Current Market Cap: 537.6B INR
For a thorough assessment of GLENMARK stock, go to TipRanks’ Stock Analysis page.